Videos

In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.

Ensuring Quality & Compliance in Pharmaceutical Raw Materials: gChem’s Approach to ICH Q7 and Supply Chain Integrity

In this interview, Rishi Pimentel of gChem explains how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, supports advanced therapies with superior purity and sterility, mitigates risks of using industrial-grade solvents, and strengthens regulatory readiness and supply chain security.

Why PROCIPIENT® Sets the Standard for the Critical Role of High Purity Solvents in Complex Drug Delivery Systems!

In this interview, Dr Nigel Langley of gChem discusses the importance of excipient grade, compliance, and supply chain transparency, and introduces PROCIPIENT®, gChem’s high-purity pharmaceutical-grade DMSO.

The Importance of Excipient Grade

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify complexity, accelerate development, and deliver therapies to patients faster. 

An End-to-End Enabler of Biologic Innovation

Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market successfully.

Fresenius Kabi Contract Manufacturing: Focused on Your Success

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs 

Training Centers and eCommerce: A Look Into Federal Equipment Company’s Pharma Innovations

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise. 

From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities

Dave Wood, CEO at Experic, discusses how decades of expertise with advanced technologies helps pharmaceutical and biotech partners bring products to market faster.

Inside Experic: Revolutionizing CDMO & Clinical Packaging Services

How gChem (formerly Gaylord Chemicals) is embracing its rebrand that aligns with green chemistry, innovation, and regulatory excellence

Gaylord Chemical is Now gChem

How BioDuro is expanding its global CRDMO footprint by improving integrated capabilities and delivering high-quality, end-to-end solutions for drug development and manufacturing

BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation

How Lonza Capsules & Health Ingredients (CHI) is redefining drug delivery with cutting-edge capsule innovation, customer-first service, and a strong commitment to sustainability

Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs

Innovative drug delivery solutions are evolving due to advances in biotechnology and the demand for biologics, focusing on user-friendly devices that improve patient compliance and support high-viscosity, large-volume treatments and various therapies.

Driving Innovation in Drug Delivery: Stevanato Group’s Integrated Solutions for Evolving Patient Needs

Dean Bornilla, Pace® Life Sciences, highlights his organization's future role in supporting biopharmaceutical development and manufacturing coast-to-coast.

Major Growth & Investment at Pace® Life Sciences  

Colbert Packaging specializes in safe, smart, and sustainable paperboard packaging for the pharmaceutical and healthcare industries, differentiating itself through industry-focused investments and a commitment to environmental responsibility.


Safe, Smart, and Sustainable Packaging for the Healthcare Industry

Dr Rupa Pike, Sr. Director & Global Head Strategic Alliances and Field Scientists for Cell Therapy, Catalent, shares insight on de-risking cell therapy programs using streamlined development and manufacturing platforms.


From Early Development to Commercialization: Strategies for Successful Cell Therapy Manufacturing

David McErlane, Group President of Biologics, Catalent, reacts to trends in cell and gene therapy development and manufacturing and comments on Catalent's ESG strategy to support people, the environment, and communities.


Sponsored Videos